SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining attention, with community members actively discussing its potential within the Real World Asset (RWA) space. Conversations are centered on potential partnerships and data adoption, with some speculating on future price movements. The broader crypto market and potential impacts from movements in coins like BTC and SOL are also being considered.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to speculation around a potential equity stake from the Trump administration to secure rare earth mineral supply chains, with community members drawing comparisons to similar situations with other companies. The community is actively discussing the potential impact on the stock price and related plays, as well as the significance of securing Greenland's resources. There is also excitement about the company's increased ownership stake in the Tanbreez project and anticipation for upcoming news.

Aventus Network

Aventus Network ($AVT) is trending as community members discuss its potential for a breakout, citing its strong chart setup, real-world partnerships (Vodafone, Heathrow), and Polkadot integration. Traders are closely monitoring volume as a key indicator, with some believing the token is undervalued and poised for significant upside. The community also notes $AVT's low market cap as a factor for potential growth.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as community members discuss its potential, citing its meme ETP launch in Europe, AI mini-bot partnership, and trading bot with automatic burns as possible catalysts. Comparisons to SHIB are being made, with some arguing FLOKI is better positioned for growth due to its lower token supply and focus on delivering promises. Bullish sentiment is fueled by anticipation of altcoin season and speculation on potential price increases.

The project was established through the BAGS.FM app which is platform that allows projects to create projects with cause, our project directly generates trading fees and processes them through the BAGS app to directly donate towards the official Dolphin Project - We're the first crypto token to passively provide donations and change to acquatic life and have already raised $8,000 towards providing sactuary for captured dolphins.

Dolphin

Dolphin Crypto ($DOLPHIN) is trending amid community excitement around its chart and potential breakout, particularly on Phantom Wallet. Discussions highlight bullish momentum and anticipation of a significant price movement, with many calling for it to reach the moon. The crypto is also discussed in the context of Solana-based meme coins, alongside tokens like $SOL, $PEPE and $SHIB.

Australian Dollar Stablecoins. Representing one of the largest sovereign currencies in the APAC region on the blockchain.

Novatti Australian Digital Dollar

Novatti Australian Digital Dollar ($AUDD) is trending as the community discusses Coinbase's decision to put the market in "cancel-only" mode, leading to concerns about potential losses and accusations of market manipulation. Some users are drawing parallels to past incidents with other cryptocurrencies and considering legal action, while others remain optimistic about the asset's potential.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies ($ADUR) is trending due to increasing interest in its plastic recycling technology and upcoming industry presentations. The community is focused on the company's potential to disrupt the $200B recycling market with its Hydrochemolytic technology, transforming waste into valuable fuels and chemicals. Positive sentiment is fueled by upcoming catalysts, like the nearing commissioning of its pilot plant, and analysts projecting significant upside.

Avino Silver & Gold Mines Ltd. engages in the mining and exploration activities. It focuses on silver reserves in the Durango region of North Central Mexico. It operates through the Silver, Gold, and Copper segments. The company was founded on May 15, 1968 and is headquartered in Vancouver, Canada.

Avino Silver & Gold Mines Ltd.

Avino Silver & Gold Mines is trending as investors discuss the company's inclusion in the Global Junior Gold Miners Index and strong Q2 results. Community members are speculating on whether the stock's recent momentum will lead to a sustained uptrend, with some eyeing it as a potential acquisition target amid rising silver prices and inclusion in the TSX30 index. Bullish sentiment also revolves around Avino's La Preciosa project and expanded production capacity, though some traders note the stock's lagging performance compared to the metals.

Tether (USDT) is a cryptocurrency with a value meant to mirror the value of the U.S. dollar. The idea was to create a stable cryptocurrency that can be used like digital dollars. Coins that serve this purpose of being a stable dollar substitute are called “stable coins.” Tether is the most popular stable coin and even acts as a dollar replacement on many popular exchanges! According to their site, Tether converts cash into digital currency, to anchor or “tether” the value of the coin to the price of national currencies like the US dollar, the Euro, and the Yen. Like other cryptos it uses blockchain. Unlike other cryptos, it is [according to the official Tether site] “100% backed by USD” (USD is held in reserve). The primary use of Tether is that it offers some stability to the otherwise volatile crypto space and offers liquidity to exchanges who can’t deal in dollars and with banks (for example to the sometimes controversial but leading exchange Bitfinex).  The digital coins are issued by a company called Tether Limited that is governed by the laws of the British Virgin Islands, according to the legal part of its website. It is incorporated in Hong Kong. It has emerged that Jan Ludovicus van der Velde is the CEO of cryptocurrency exchange Bitfinex, which has been accused of being involved in the price manipulation of bitcoin, as well as tether. Many people trading on exchanges, including Bitfinex, will use tether to buy other cryptocurrencies like bitcoin. Tether Limited argues that using this method to buy virtual currencies allows users to move fiat in and out of an exchange more quickly and cheaply. Also, exchanges typically have rocky relationships with banks, and using Tether is a way to circumvent that.  USDT is fairly simple to use. Once on exchanges like Poloniex or Bittrex, it can be used to purchase Bitcoin and other cryptocurrencies. It can be easily transferred from an exchange to any Omni Layer enabled wallet. Tether has no transaction fees, although external wallets and exchanges may charge one. In order to convert USDT to USD and vise versa through the Tether.to Platform, users must pay a small fee. Buying and selling Tether for Bitcoin can be done through a variety of exchanges like the ones mentioned previously or through the Tether.to platform, which also allows the conversion between USD to and from your bank account.

Tether

Tether is trending due to its connections with Rumble, including a potential Rumble wallet integration and existing cloud service partnerships. The community is discussing Tether's significant ownership stake in Rumble and the potential impact of its treasury on the platform's growth. Broader conversations include Tether's role in the crypto ecosystem and its potential expansion into new ventures.

Energous Corp. engages in the development of wireless charging technology. It focuses on the product, WattUp, a wireless power technology consisting of proprietary semiconductor chipsets, software controls, hardware designs, and antennas, that enables radio frequency based charging for electronic devices. The company was founded by Michael Aaron Leabman in 2012 and is headquartered in San Jose, CA.

Energous Corp

Energous Corp is trending as investors discuss the potential impact of Walmart's partnership with Wiliot, speculating on whether Energous' wireless power technology is involved in the deal. Community members are debating the company's growth prospects, revenue, and potential for a short squeeze, while also considering the broader context of small-cap stocks and the wireless charging market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Travere Therapeutics (TVTX) on Wednesday said that the U.S. Food and Drug Administration informed the company that it has waived the need for an advisory committee meeting regarding its application for Filspari in treating focal segmental glomerulosclerosis (FSGS).The FDA is expected to decide on the company’s application by January 13, 2026. If approved, Filspari would be the first medication indicated for FSGS, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250910301976/en/Travere-Therapeutics-Provides-Update-on-FDA-Advisory-Committee-Meeting-for-FILSPARI-sparsentan-in-FSGS">said</a>. FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure and is estimated to affect more than 40,000 patients in the U.S., according to Travere. &nbsp;Shares of the company soared 16% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CEO Eric Dube said that the company is pleased with the progress of its new application for Filspari to date and is continuing preparation for a successful commercial launch in January, if approved.The company’s application is supported by data from mid-stage and late-stage studies where Filspari demonstrated rapid, superior, and sustained reductions in proteinuria when compared with the maximum labeled dose of the approved drug Irbesartan across adult and pediatric patients. The drug was also well-tolerated in the studies with a safety profile comparable to Irbesartan.Filspari is already approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units. The new application by the company seeks to expand its use to the treatment of FSGS as well.TVTX stock is up by 24% this year and by about 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-stock-rises-pre-market-after-company-announces-positive-efficacy-data-for-agitation-drug-in-study/chwk7aERdub">BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 

Equity

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 


Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of +50.00% and +17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics shares tumbled over 15% in extended trading Thursday after the company said the U.S. Food and Drug Administration will convene an advisory committee meeting to review a supplemental use of its kidney drug, Filspari.The FDA accepted Travere's supplemental New Drug Application (sNDA) seeking traditional approval of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tvtx-stock-soars-on-fda-approval-plan-for-filspari/ch57VA1RMt">Filspari</a> for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disorder with no FDA-approved therapies.&nbsp;Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026."We are one step closer to potentially delivering the first approved treatment for people living with FSGS - a leading cause of kidney failure and devastating condition that urgently needs new treatment options," said CEO Eric Dube.While the advisory committee (AdComm) meeting introduces an added review step, it is a standard part of the FDA's drug approval process and not necessarily a red flag. However, negative recommendations from such meetings can lead to delays or rejections.Despite the market reaction, sentiment on Stocktwits ended 'extremely bullish' on Thursday, with message volume jumping from 'normal' to 'high.' Some retail traders saw the selloff as overdone.<figure class="image"><img style="aspect-ratio:1318/192;" src="https://news.stocktwits-cdn.com/TVTX_sentiment_and_message_volume_as_of_May_15_png_4829a2c988.webp" alt="TVTX sentiment and message volume as of May 15.png" width="1318" height="192"><figcaption>TVTX sentiment and message volume as of May 15. | source: Stocktwits</figcaption></figure>"Oversold now.&nbsp; It's an ADCOM, and by no means a bad thing when a meeting is required. It boils down to a safe and highly needed prescription drug, that just needs to thread the needle of the FDA," one user wrote.<stembedurl>https://stocktwits.com/FloatTrip/message/614839023</stembedurl>"From late fall to just January 2026, is not that big of a deal to wait to get the "T's" crossed and the "I's" dotted. A few months added from the original timeframe," another said, brushing off the timeline shift.<stembedurl>https://stocktwits.com/FloatTrip/message/614836495</stembedurl>However, investors often cheer when the FDA skips an AdComm — as seen in March, when Tonix Pharma stock surged on news its fibromyalgia drug would not require such a review.Filspari is already approved to slow kidney function decline in IgA nephropathy, another rare kidney condition. FSGS affects more than 40,000 patients in the U.S., and Travere is seeking to expand Filspari's label for this population.<a href="https://stocktwits.com/symbol/TVTX">Travere shares</a> are up over 19% year to date, but short interest has climbed, rising from 8.5% at the start of 2025 to 11.9% as of last week, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries

Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.

Shares of Travere Therapeutics Inc. surged over 13% Tuesday afternoon, reaching their highest level since October 2022 and driving a spike in retail discussions on Stocktwits.The rally followed Travere’s announcement that it plans to seek full FDA approval for Filspari in treating focal segmental glomerulosclerosis (FSGS), a rare kidney disorder.&nbsp;The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.According to The Fly, Wells Fargo sees the accelerated timeline as a strong positive. It estimates a 60%- 70% probability of success, which it models as a fair value range of $27-$30 per share.&nbsp;At full approval, the firm values the stock at $40 per share, but currently maintains an ‘Overweight’ rating with a $27 price target.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TVTX_sentiment_and_message_volume_Feb_11_40f540ed9b.png" alt="TVTX sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TVTX sentiment and message volume Feb 11 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Stocktwits sentiment for Travere turned ‘bullish,’ with message volume (81/100) hitting a three-month high.&nbsp;Retail traders cheered the news, with some analyzing technical patterns signaling further gains.&nbsp;<stembedurl>https://stocktwits.com/Frostblade91/message/603708895</stembedurl><stembedurl>https://stocktwits.com/RonIsWrong/message/603732744</stembedurl>FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S., with no current FDA-approved treatments.&nbsp;Filspari has already been approved to slow kidney function decline in adults with IgA nephropathy.Shares of Travere have nearly tripled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.30	--	--	N/A
Q2 '25	-$0.31	-$0.14	55.08%	BEAT
Q1 '25	-$0.57	-$0.47	17.11%	BEAT
Q4 '24	-$0.56	-$0.73	-29.89%	MISSED
Q3 '24	-$0.64	-$0.70	-9.39%	MISSED

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TVTX News

TVTX Travere Therapeutics Inc